ParkinsonFranceV1, PascalFrancis, Corpus, bibRecord, 001A50

Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy

Identifieur interne : 001A50 ( PascalFrancis/Corpus ); précédent : 001A49; suivant : 001A51

Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy

Auteurs : J. M. Senard ; O. Rascol ; G. Durrieu ; M. A. Tran ; M. Berlan ; A. Rascol ; J. L. Montastruc

Source :

Clinical neuropharmacology [ 0362-5664 ] ; 1993.

RBID : Pascal:93-0406320

Descripteurs français

Pascal (Inist)
- Bloquant α-adrénergique, Mécanisme action, Homme, Voie orale, Catécholamine, Hypotension artérielle orthostatique, Parkinson maladie, Dégénérescence neuronale présénile Shy Drager, Hypertenseur, Yohimbine.

English descriptors

KwdEn :
- Alpha blocking agent, Catecholamine, Human, Hypertensive drug, Mechanism of action, Oral administration, Parkinson disease, Postural hypotension, Shy Drager presenile neuronal degeneration.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0362-5664`
A02	`01`			`@0 CLNEDB`
A03		`1`		`@0 Clin. neuropharmacol.`
A05				`@2 16`
A06				`@2 1`
A08	`01`	`1`	`ENG`	`@1 Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy`
A11	`01`	`1`		`@1 SENARD (J. M.)`
A11	`02`	`1`		`@1 RASCOL (O.)`
A11	`03`	`1`		`@1 DURRIEU (G.)`
A11	`04`	`1`		`@1 TRAN (M. A.)`
A11	`05`	`1`		`@1 BERLAN (M.)`
A11	`06`	`1`		`@1 RASCOL (A.)`
A11	`07`	`1`		`@1 MONTASTRUC (J. L.)`
A14	`01`			`@1 INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin. @2 31073 Toulouse @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut.`
A20				`@1 70-76`
A21				`@1 1993`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16720 @5 354000038534060080`
A44				`@0 0000`
A45				`@0 20 ref.`
A47	`01`	`1`		`@0 93-0406320`
A60				`@1 P @3 CC`
A61				`@0 A`
A64		`1`		`@0 Clinical neuropharmacology`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02F09`
C03	`01`	`X`	`FRE`	`@0 Bloquant α-adrénergique`
C03	`01`	`X`	`ENG`	`@0 Alpha blocking agent`
C03	`01`	`X`	`SPA`	`@0 Bloqueador α-adrenérgico`
C03	`02`	`X`	`FRE`	`@0 Mécanisme action`
C03	`02`	`X`	`ENG`	`@0 Mechanism of action`
C03	`02`	`X`	`SPA`	`@0 Mecanismo acción`
C03	`03`	`X`	`FRE`	`@0 Homme`
C03	`03`	`X`	`ENG`	`@0 Human`
C03	`03`	`X`	`SPA`	`@0 Hombre`
C03	`04`	`X`	`FRE`	`@0 Voie orale`
C03	`04`	`X`	`ENG`	`@0 Oral administration`
C03	`04`	`X`	`SPA`	`@0 Vía oral`
C03	`05`	`X`	`FRE`	`@0 Catécholamine`
C03	`05`	`X`	`ENG`	`@0 Catecholamine`
C03	`05`	`X`	`SPA`	`@0 Catecolamina`
C03	`06`	`X`	`FRE`	`@0 Hypotension artérielle orthostatique @2 NM`
C03	`06`	`X`	`ENG`	`@0 Postural hypotension @2 NM`
C03	`06`	`X`	`SPA`	`@0 Hipotensión arterial ortostática @2 NM`
C03	`07`	`X`	`FRE`	`@0 Parkinson maladie @2 NM`
C03	`07`	`X`	`ENG`	`@0 Parkinson disease @2 NM`
C03	`07`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM`
C03	`08`	`X`	`FRE`	`@0 Dégénérescence neuronale présénile Shy Drager @2 NM`
C03	`08`	`X`	`ENG`	`@0 Shy Drager presenile neuronal degeneration @2 NM`
C03	`08`	`X`	`SPA`	`@0 Degeneración neuronal presenil Shy Drager @2 NM`
C03	`09`	`X`	`FRE`	`@0 Hypertenseur`
C03	`09`	`X`	`ENG`	`@0 Hypertensive drug`
C03	`09`	`X`	`SPA`	`@0 Hipertensor`
C03	`10`	`X`	`FRE`	`@0 Yohimbine @2 FR @4 INC`
C07	`01`	`X`	`FRE`	`@0 Appareil circulatoire pathologie`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa`
C07	`04`	`X`	`FRE`	`@0 Système nerveux sympathique pathologie`
C07	`04`	`X`	`ENG`	`@0 Autonomic neuropathy`
C07	`04`	`X`	`SPA`	`@0 Sistema nervioso simpático patología`
N21				`@1 161`

Format Inist (serveur)

NO :	PASCAL 93-0406320 INIST
ET :	Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy
AU :	SENARD (J. M.); RASCOL (O.); DURRIEU (G.); TRAN (M. A.); BERLAN (M.); RASCOL (A.); MONTASTRUC (J. L.)
AF :	INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin./31073 Toulouse/France (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Clinical neuropharmacology; ISSN 0362-5664; Coden CLNEDB; Etats-Unis; Da. 1993; Vol. 16; No. 1; Pp. 70-76; Bibl. 20 ref.
LA :	Anglais
CC :	002B02F09
FD :	Bloquant α-adrénergique; Mécanisme action; Homme; Voie orale; Catécholamine; Hypotension artérielle orthostatique; Parkinson maladie; Dégénérescence neuronale présénile Shy Drager; Hypertenseur; Yohimbine
FG :	Appareil circulatoire pathologie; Système nerveux pathologie; Maladie dégénérative; Système nerveux sympathique pathologie
ED :	Alpha blocking agent; Mechanism of action; Human; Oral administration; Catecholamine; Postural hypotension; Parkinson disease; Shy Drager presenile neuronal degeneration; Hypertensive drug
EG :	Cardiovascular disease; Nervous system diseases; Degenerative disease; Autonomic neuropathy
SD :	Bloqueador α-adrenérgico; Mecanismo acción; Hombre; Vía oral; Catecolamina; Hipotensión arterial ortostática; Parkinson enfermedad; Degeneración neuronal presenil Shy Drager; Hipertensor
LO :	INIST-16720.354000038534060080
ID :	93-0406320

Links to Exploration step

Pascal:93-0406320

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy</title>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Durrieu, G" sort="Durrieu, G" uniqKey="Durrieu G" first="G." last="Durrieu">G. Durrieu</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tran, M A" sort="Tran, M A" uniqKey="Tran M" first="M. A." last="Tran">M. A. Tran</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berlan, M" sort="Berlan, M" uniqKey="Berlan M" first="M." last="Berlan">M. Berlan</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">93-0406320</idno>
<date when="1993">1993</date>
<idno type="stanalyst">PASCAL 93-0406320 INIST</idno>
<idno type="RBID">Pascal:93-0406320</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A50</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy</title>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Durrieu, G" sort="Durrieu, G" uniqKey="Durrieu G" first="G." last="Durrieu">G. Durrieu</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tran, M A" sort="Tran, M A" uniqKey="Tran M" first="M. A." last="Tran">M. A. Tran</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Berlan, M" sort="Berlan, M" uniqKey="Berlan M" first="M." last="Berlan">M. Berlan</name>
<affiliation><inist:fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
</author>
</analytic>
<series><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="1993">1993</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alpha blocking agent</term>
<term>Catecholamine</term>
<term>Human</term>
<term>Hypertensive drug</term>
<term>Mechanism of action</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Postural hypotension</term>
<term>Shy Drager presenile neuronal degeneration</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Bloquant α-adrénergique</term>
<term>Mécanisme action</term>
<term>Homme</term>
<term>Voie orale</term>
<term>Catécholamine</term>
<term>Hypotension artérielle orthostatique</term>
<term>Parkinson maladie</term>
<term>Dégénérescence neuronale présénile Shy Drager</term>
<term>Hypertenseur</term>
<term>Yohimbine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0362-5664</s0>
</fA01>
<fA02 i1="01"><s0>CLNEDB</s0>
</fA02>
<fA03 i2="1"><s0>Clin. neuropharmacol.</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>1</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>SENARD (J. M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>RASCOL (O.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DURRIEU (G.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>TRAN (M. A.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BERLAN (M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>RASCOL (A.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MONTASTRUC (J. L.)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin.</s1>
<s2>31073 Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>70-76</s1>
</fA20>
<fA21><s1>1993</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16720</s2>
<s5>354000038534060080</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>20 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>93-0406320</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Clinical neuropharmacology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02F09</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Bloquant α-adrénergique</s0>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Alpha blocking agent</s0>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Bloqueador α-adrenérgico</s0>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Mécanisme action</s0>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Mechanism of action</s0>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Mecanismo acción</s0>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Homme</s0>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Human</s0>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hombre</s0>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Voie orale</s0>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Oral administration</s0>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vía oral</s0>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Catécholamine</s0>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Catecholamine</s0>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Catecolamina</s0>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Hypotension artérielle orthostatique</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Postural hypotension</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Hipotensión arterial ortostática</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Dégénérescence neuronale présénile Shy Drager</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Shy Drager presenile neuronal degeneration</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Degeneración neuronal presenil Shy Drager</s0>
<s2>NM</s2>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Hypertenseur</s0>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Hypertensive drug</s0>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hipertensor</s0>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Yohimbine</s0>
<s2>FR</s2>
<s4>INC</s4>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux sympathique pathologie</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Autonomic neuropathy</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso simpático patología</s0>
</fC07>
<fN21><s1>161</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 93-0406320 INIST</NO>
<ET>Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy</ET>
<AU>SENARD (J. M.); RASCOL (O.); DURRIEU (G.); TRAN (M. A.); BERLAN (M.); RASCOL (A.); MONTASTRUC (J. L.)</AU>
<AF>INSERM CHU Purpan, fac. médecine, lab. pharmacologie médicale clin./31073 Toulouse/France (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Clinical neuropharmacology; ISSN 0362-5664; Coden CLNEDB; Etats-Unis; Da. 1993; Vol. 16; No. 1; Pp. 70-76; Bibl. 20 ref.</SO>
<LA>Anglais</LA>
<CC>002B02F09</CC>
<FD>Bloquant α-adrénergique; Mécanisme action; Homme; Voie orale; Catécholamine; Hypotension artérielle orthostatique; Parkinson maladie; Dégénérescence neuronale présénile Shy Drager; Hypertenseur; Yohimbine</FD>
<FG>Appareil circulatoire pathologie; Système nerveux pathologie; Maladie dégénérative; Système nerveux sympathique pathologie</FG>
<ED>Alpha blocking agent; Mechanism of action; Human; Oral administration; Catecholamine; Postural hypotension; Parkinson disease; Shy Drager presenile neuronal degeneration; Hypertensive drug</ED>
<EG>Cardiovascular disease; Nervous system diseases; Degenerative disease; Autonomic neuropathy</EG>
<SD>Bloqueador α-adrenérgico; Mecanismo acción; Hombre; Vía oral; Catecolamina; Hipotensión arterial ortostática; Parkinson enfermedad; Degeneración neuronal presenil Shy Drager; Hipertensor</SD>
<LO>INIST-16720.354000038534060080</LO>
<ID>93-0406320</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A50 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001A50 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:93-0406320
   |texte=   Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy

Effects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri